IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023
LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development…
Month: March 2023
Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., March 23, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., March 23, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”)…
Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”)…
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
– Company ended the year with $50.6 million in cash, expected to fund operations through…
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
– Company ended the year with $50.6 million in cash, expected to fund operations through…
Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update
Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2…
Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update
Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2…
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results
On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the…
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results
On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the…
Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA),…
Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA),…
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
Company to host an investor conference call and webcast at 4:30 pm ET NEW YORK,…
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
Company to host an investor conference call and webcast at 4:30 pm ET NEW YORK,…
Valitor to Present at the Association for Research in Vision and Ophthalmology Annual Meeting
BERKELEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering better medicines…
Valitor to Present at the Association for Research in Vision and Ophthalmology Annual Meeting
BERKELEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering better medicines…
Nautilus Biotechnology to Participate in B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a…
Nautilus Biotechnology to Participate in B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a…
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
March 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s…